Invasive intraductal papillary mucinous neoplasm: Predictors of survival and role of adjuvant therapy

Olivier Turrini, Joshua A. Waters, Thomas Schnelldorfer, Keith D. Lillemoe, Constantin Yiannoutsos, Michael B. Farnell, Michael G. Sarr, C. Schmidt

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Adjuvant treatment for pancreatic adenocarcinoma has been shown to improve survival. An increasingly recognized 'subtype' of pancreatic adenocarcinoma is invasive intraductal papillary mucinous neoplasm (IPMN). It is unclear whether adjuvant treatment for invasive IPMN improves survival. This study aimed to determine the impact of adjuvant treatment in invasive IPMN. Methods: We conducted a retrospective analysis of merged clinical databases including 412 patients undergoing resection for IPMN at two academic institutions between 1989 and 2006. Results: Of 412 patients with IPMN who underwent pancreatectomy, 98 had invasive carcinoma. Median survival in invasive IPMN was 32 months. Adjuvant treatment did not affect median survival in node-positive or node-negative invasive IPMN. Biopsy-proven recurrence of invasive IPMN occurred in 45 patients (46%). The median disease-free interval from resection to recurrence was 27 months. Treatment of recurrences with chemotherapy or radiation therapy was not associated with a difference in survival; however, a subgroup of patients with recurrence in the remnant pancreas who underwent re-resection appeared to have more favourable outcomes. Conclusions: An invasive component measuring >2 cm and lymph node involvement are associated with poorer prognosis. Adjuvant therapy in invasive IPMN appears to confer no survival benefit. In selected patients with recurrence of invasive IPMN in the remnant pancreas, re-resection should be considered.

Original languageEnglish
Pages (from-to)447-455
Number of pages9
JournalHPB
Volume12
Issue number7
DOIs
StatePublished - Sep 2010

Fingerprint

Survival
Neoplasms
Recurrence
Therapeutics
Pancreas
Adenocarcinoma
Pancreatectomy
Radiotherapy
Lymph Nodes
Databases
Carcinoma
Biopsy
Drug Therapy

Keywords

  • Adjuvant treatment
  • Intraductal papillary mucinous neoplasm
  • Invasive

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Invasive intraductal papillary mucinous neoplasm : Predictors of survival and role of adjuvant therapy. / Turrini, Olivier; Waters, Joshua A.; Schnelldorfer, Thomas; Lillemoe, Keith D.; Yiannoutsos, Constantin; Farnell, Michael B.; Sarr, Michael G.; Schmidt, C.

In: HPB, Vol. 12, No. 7, 09.2010, p. 447-455.

Research output: Contribution to journalArticle

Turrini, Olivier ; Waters, Joshua A. ; Schnelldorfer, Thomas ; Lillemoe, Keith D. ; Yiannoutsos, Constantin ; Farnell, Michael B. ; Sarr, Michael G. ; Schmidt, C. / Invasive intraductal papillary mucinous neoplasm : Predictors of survival and role of adjuvant therapy. In: HPB. 2010 ; Vol. 12, No. 7. pp. 447-455.
@article{be9414a1b9e6400dae7e77ba5a3fc612,
title = "Invasive intraductal papillary mucinous neoplasm: Predictors of survival and role of adjuvant therapy",
abstract = "Background: Adjuvant treatment for pancreatic adenocarcinoma has been shown to improve survival. An increasingly recognized 'subtype' of pancreatic adenocarcinoma is invasive intraductal papillary mucinous neoplasm (IPMN). It is unclear whether adjuvant treatment for invasive IPMN improves survival. This study aimed to determine the impact of adjuvant treatment in invasive IPMN. Methods: We conducted a retrospective analysis of merged clinical databases including 412 patients undergoing resection for IPMN at two academic institutions between 1989 and 2006. Results: Of 412 patients with IPMN who underwent pancreatectomy, 98 had invasive carcinoma. Median survival in invasive IPMN was 32 months. Adjuvant treatment did not affect median survival in node-positive or node-negative invasive IPMN. Biopsy-proven recurrence of invasive IPMN occurred in 45 patients (46{\%}). The median disease-free interval from resection to recurrence was 27 months. Treatment of recurrences with chemotherapy or radiation therapy was not associated with a difference in survival; however, a subgroup of patients with recurrence in the remnant pancreas who underwent re-resection appeared to have more favourable outcomes. Conclusions: An invasive component measuring >2 cm and lymph node involvement are associated with poorer prognosis. Adjuvant therapy in invasive IPMN appears to confer no survival benefit. In selected patients with recurrence of invasive IPMN in the remnant pancreas, re-resection should be considered.",
keywords = "Adjuvant treatment, Intraductal papillary mucinous neoplasm, Invasive",
author = "Olivier Turrini and Waters, {Joshua A.} and Thomas Schnelldorfer and Lillemoe, {Keith D.} and Constantin Yiannoutsos and Farnell, {Michael B.} and Sarr, {Michael G.} and C. Schmidt",
year = "2010",
month = "9",
doi = "10.1111/j.1477-2574.2010.00196.x",
language = "English",
volume = "12",
pages = "447--455",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Invasive intraductal papillary mucinous neoplasm

T2 - Predictors of survival and role of adjuvant therapy

AU - Turrini, Olivier

AU - Waters, Joshua A.

AU - Schnelldorfer, Thomas

AU - Lillemoe, Keith D.

AU - Yiannoutsos, Constantin

AU - Farnell, Michael B.

AU - Sarr, Michael G.

AU - Schmidt, C.

PY - 2010/9

Y1 - 2010/9

N2 - Background: Adjuvant treatment for pancreatic adenocarcinoma has been shown to improve survival. An increasingly recognized 'subtype' of pancreatic adenocarcinoma is invasive intraductal papillary mucinous neoplasm (IPMN). It is unclear whether adjuvant treatment for invasive IPMN improves survival. This study aimed to determine the impact of adjuvant treatment in invasive IPMN. Methods: We conducted a retrospective analysis of merged clinical databases including 412 patients undergoing resection for IPMN at two academic institutions between 1989 and 2006. Results: Of 412 patients with IPMN who underwent pancreatectomy, 98 had invasive carcinoma. Median survival in invasive IPMN was 32 months. Adjuvant treatment did not affect median survival in node-positive or node-negative invasive IPMN. Biopsy-proven recurrence of invasive IPMN occurred in 45 patients (46%). The median disease-free interval from resection to recurrence was 27 months. Treatment of recurrences with chemotherapy or radiation therapy was not associated with a difference in survival; however, a subgroup of patients with recurrence in the remnant pancreas who underwent re-resection appeared to have more favourable outcomes. Conclusions: An invasive component measuring >2 cm and lymph node involvement are associated with poorer prognosis. Adjuvant therapy in invasive IPMN appears to confer no survival benefit. In selected patients with recurrence of invasive IPMN in the remnant pancreas, re-resection should be considered.

AB - Background: Adjuvant treatment for pancreatic adenocarcinoma has been shown to improve survival. An increasingly recognized 'subtype' of pancreatic adenocarcinoma is invasive intraductal papillary mucinous neoplasm (IPMN). It is unclear whether adjuvant treatment for invasive IPMN improves survival. This study aimed to determine the impact of adjuvant treatment in invasive IPMN. Methods: We conducted a retrospective analysis of merged clinical databases including 412 patients undergoing resection for IPMN at two academic institutions between 1989 and 2006. Results: Of 412 patients with IPMN who underwent pancreatectomy, 98 had invasive carcinoma. Median survival in invasive IPMN was 32 months. Adjuvant treatment did not affect median survival in node-positive or node-negative invasive IPMN. Biopsy-proven recurrence of invasive IPMN occurred in 45 patients (46%). The median disease-free interval from resection to recurrence was 27 months. Treatment of recurrences with chemotherapy or radiation therapy was not associated with a difference in survival; however, a subgroup of patients with recurrence in the remnant pancreas who underwent re-resection appeared to have more favourable outcomes. Conclusions: An invasive component measuring >2 cm and lymph node involvement are associated with poorer prognosis. Adjuvant therapy in invasive IPMN appears to confer no survival benefit. In selected patients with recurrence of invasive IPMN in the remnant pancreas, re-resection should be considered.

KW - Adjuvant treatment

KW - Intraductal papillary mucinous neoplasm

KW - Invasive

UR - http://www.scopus.com/inward/record.url?scp=77956904816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956904816&partnerID=8YFLogxK

U2 - 10.1111/j.1477-2574.2010.00196.x

DO - 10.1111/j.1477-2574.2010.00196.x

M3 - Article

C2 - 20815853

AN - SCOPUS:77956904816

VL - 12

SP - 447

EP - 455

JO - HPB

JF - HPB

SN - 1365-182X

IS - 7

ER -